BioSpace News Archive

Panbela Therapeutics, Inc today announced that an abstract about SBP-101 and CPP-1X (also known as DFMO or Eflornithine) research in multiple myeloma (cell lines), has been accepted for an online publication on the American Society of Hematology (ASH) meeting site in the November supplemental issue of the journal Blood.

ImmunoPrecise Antibodies Ltd. announces that its subsidiary, BioStrand®, has commercially launched its state-of-the-art Retrieval Augmented Generation -based Large Language Model platform.

BioInvent International invites investors, analysts and the press to a presentation of the interim report January- September 2023 at 2:00 pm on Thursday October 26. The report will be published at 8:00 am CET the same day. BioInvent’s CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When:

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the market.

Vericel Corporation today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023.

Hepion Pharmaceuticals, Inc. announced the publication of a new research study in mice, where Hepion’s lead drug candidate, rencofilstat, prevented the growth of liver tumors that occurred as a result of chronic infection with the human hepatitis C virus (“HCV”).

Enterome today announces that Pierre Bélichard, CEO, will present an overview of the Company and participate in 1-on-1 meetings with institutional investors at the following investor meetings.

Akebia Therapeutics today announced the U.S. Food and Drug Administration (FDA) has acknowledged that the resubmission to its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis, was complete.

COVID is an acute disease that comes and goes, but for a growing number of people, the sequelae to the infection - the aftereffects - can become a constellation of symptoms called long COVID that may affect sufferers for years, if not a lifetime.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.